Table 1.
Baseline for pCCA patients categorized by NLR, PLR and their clinical pathological characteristics.
| Variables | NLR | PLR | ||||
|---|---|---|---|---|---|---|
| < 1.68 (n = 155) | ≥ 1.68 (n = 178) | P value | < 113.1 (n = 231) | ≥113.1 (n = 102) | P value | |
| Age, years* | 56.89 ± 10.73 | 57.15 ± 9.22 | 0.815 | 56.51 ± 10.19 | 58.20 ± 9.29 | 0.154 |
| Gender, male | 101 (65.16) | 112 (62.9) | 0.671 | 149 (64.5) | 64 (62.7) | 0.758 |
| ASA score > 2 | 12 (7.7) | 22 (12.4) | 0.165 | 26 (11.6) | 8 (7.8) | 0.343 |
| Comorbidity | 40 (25.8) | 41 (23.0) | 0.556 | 60 9 (26.0) | 21 (20.6) | 0.291 |
| Preoperative jaundice | 118 (76.1) | 142 (79.8) | 0.442 | 179 (77.5) | 81 (79.4) | 0.696 |
| ALB (g/L)* | 36.27 ± 4.71 | 37.25 ± 4.23 | 0.045 | 36.71 ± 4.70 | 37.00 ± 3.94 | 0.593 |
| ALT (U/L)* | 71.00 (45.50, 157.00) | 83.50 (52.00, 169.00) | 0.927 | 73.70 (46.00, 162.00) | 81.15 (52.28, 161.00) | 0.726 |
| AST (U/L)* | 74.00 (45.00, 136.00) | 83.00 (52.75, 138.00) | 0.735 | 75.40 (49.70, 130.00) | 85.50 (49.95, 134.00) | 0.665 |
| Hb (g/L) | 121.23 ± 25.51 | 122.75 ± 23.84 | 0.576 | 122.88 ± 27.76 | 120.15 ± 15.20 | 0.352 |
| TB (mg/dL)* | 150.40 (25.70, 279.40) | 145.30 (51.95, 248.05) | 0.557 | 150.40 (46.40, 263.90) | 138.70 (32.40, 263.10) | 0.839 |
| CA 19-9 (U/L)* | 121.00(34.20, 277.17) | 140.07 (60.00, 364.65) | 0.024 | 127.38 (42.53, 308.80) | 134.52 (61.73, 400.00) | 0.200 |
| INR* | 0.97 ± 0.10 | 0.97 ± 0.10 | 0.562 | 0.96 ± 0.10 | 0.98 ± 0.11 | 0.105 |
| NLR | 1.11 ± 0.32 | 3.15 ± 1.45 | <0.001 | 1.76 ± 1.06 | 3.18 ± 1.81 | <0.001 |
| PLR | 55.00 (38.92, 81.94) | 107.27 (68.53, 144.45) | <0.001 | 60.00 (42.97, 81.25) | 144.68 (126.88, 185.31) | <0.001 |
| Cirrhosis | 15 (9.7) | 14 (7.8) | 0.559 | 25 (10.8) | 4 (3.9) | 0.04 |
| Chronic hepatitis | 13 (9.0) | 14 (7.8) | 0.862 | 18 (7,8) | 9 (8.8) | 0.751 |
| Hepatolithiasis | 14 (8.3) | 10 (5.6) | 0.229 | 20 (8.7) | 4 (3.9) | 0.123 |
| Maximum tumor size (cm)* | 2.84 ± 1.24 | 3.05 ± 1.39 | 0.137 | 2.91 ± 1.26 | 3.05 ± 1.47 | 0.370 |
| Poor differentiation | 15 (9.7) | 34 (19.1) | 0.015 | 31 (13.4) | 18 (17.6) | 0.316 |
| Macrovascular invasion | 34 (21.9) | 53 (29.8) | 0.104 | 54 (23.4) | 33 (32.4) | 0.086 |
| Microvascular invasion | 11 (7.1) | 26 (14.6) | 0.030 | 23 (10.0) | 14 (13.7) | 0.313 |
| 8th AJCC stage III-IV | 80 (51.6) | 89 (50.0) | 0.769 | 114 (49.4) | 55 (53.9) | 0.442 |
| Bismuth classification III-IV | 121 (78.1) | 134 (75.3) | 0.550 | 183 (79.2) | 72 (70.6) | 0.086 |
| Lymph node metastasis | 48 (30.1) | 62 (34.8) | 0.455 | 67 (29.0) | 43 (42.1) | 0.019 |
| Peripheral nerve invasion | 50 (32.3) | 51 (28.7) | 0.475 | 75 (32.5) | 26 (25.5) | 0.202 |
| Intraoperative blood loss (ml) | 700.0 (400.0, 1000.0) | 700.0 (437.5, 1000.0) | 0.137 | 700.0 (400.0, 1000.0) | 700.0 (500.0, 1400.0) | 0.116 |
| Major hepatectomy | 114 (73.5) | 128 (71.9) | 0.738 | 169 (73.2) | 73 (71.6) | 0.764 |
*Values are the mean ± standard deviation or median and quartile.
AJCC, American Joint Committee on Cancer; ALB, albumin level; ALT, alanine aminotransferase; ASA, American Society of Anesthesiologists; AST, aspartate transaminase; CA 19-9, carbohydrate antigen 19-9; INR, international normalized ratio; NLR, neutrophil-to-lymphocyte ratio; pCCA, perihilar cholangiocarcinoma; PLT, platelets level; PLR, platelet-to-lymphocyte ratio; TB, total bilirubin.